Nature Reviews Drug Discovery

Back to the drawing board for anhedonia drugs

Asher Mullard May 01, 2025 pp. 319-320 10.1038/d41573-025-00073-3

Back to therapeutic modality basics

Asher Mullard May 01, 2025 pp. 327-328 10.1038/d41573-025-00072-4

FDA new drug approvals in Q1 2025

Paul Verdin May 01, 2025 pp. 324-324 10.1038/d41573-025-00071-5

Novel drug targets in 2024

Sorin Avram, Liliana Halip, Ramona Curpan et al. May 01, 2025 pp. 323-323 10.1038/d41573-025-00069-z

FDA approves siRNA drug for haemophilia prophylaxis

Asher Mullard May 01, 2025 pp. 322-322 10.1038/d41573-025-00066-2

Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease

Asher Mullard May 01, 2025 pp. 321-321 10.1038/d41573-025-00063-5

New antibiotic for urinary tract infections nabs FDA approval

Asher Mullard May 01, 2025 pp. 322-322 10.1038/d41573-025-00064-4

Publisher Correction: Fibrosis: cross-organ biology and pathways to development of innovative drugs

Florian Rieder, Laura E. Nagy, Toby M. Maher et al. May 01, 2025 pp. 399-399 10.1038/s41573-025-01190-9

Non-incretin peptide curbs appetite

M. Teresa Villanueva May 01, 2025 pp. 333-333 10.1038/d41573-025-00062-6

Two routes to tamp down microglia in traumatic brain injury

Katie Kingwell May 01, 2025 pp. 332-332 10.1038/d41573-025-00060-8

Towards an oral norovirus vaccine

Sarah Crunkhorn May 01, 2025 pp. 334-334 10.1038/d41573-025-00058-2

Identifying novel antibiotic targets

Sarah Crunkhorn May 01, 2025 pp. 334-334 10.1038/d41573-025-00059-1

Small-molecule hypoxia therapy

Sarah Crunkhorn May 01, 2025 pp. 334-334 10.1038/d41573-025-00056-4

Blocking ceramide signalling alleviates atherosclerosis

Sarah Crunkhorn May 01, 2025 pp. 334-334 10.1038/d41573-025-00057-3

Insights into new approach methodology innovation: an EMA perspective

Mariana Edwards, Oriane Blanquie, Falk Ehmann May 01, 2025 pp. 325-326 10.1038/d41573-025-00052-8

Cannabinoid targets hidden pocket for safer pain relief

Alex Eccleston May 01, 2025 pp. 331-331 10.1038/d41573-025-00055-5

A new target for cancer cachexia

Sarah Crunkhorn May 01, 2025 pp. 333-333 10.1038/d41573-025-00054-6

Clinical development success rates for durable cell and gene therapies

Sharon Phares, Katie Phillip, Mark Trusheim May 01, 2025 pp. 329-330 10.1038/d41573-025-00036-8

Novel strategies to manage CAR-T cell toxicity

Arthur Mulvey, Lionel Trueb, George Coukos et al. May 01, 2025 pp. 379-397 10.1038/s41573-024-01100-5

Voltage-gated sodium channels in excitable cells as drug targets

Matthew Alsaloum, Sulayman D. Dib-Hajj, Dana A. Page et al. May 01, 2025 pp. 358-378 10.1038/s41573-024-01108-x

FGF-based drug discovery: advances and challenges

Gaozhi Chen, Lingfeng Chen, Xiaokun Li et al. May 01, 2025 pp. 335-357 10.1038/s41573-024-01125-w